Two targeted pills for KRAS G12C tumors
Part of Cancer clinical trials.
This trial tests a new combination of two targeted pills (GH21 and D-1553) for people with advanced solid tumors that have a specific KRAS G12C mutation, especially those who have already tried another KRAS G12C inhibitor. The goal is to see if the combo can shrink tumors more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a locally advanced or metastatic solid tumor with a specific KRAS G12C mutation.
- You have already tried a KRAS G12C inhibitor (like sotorasib or adagrasib) and it stopped working or isn't available.
- You are generally up and about (ECOG score 0 or 1).
- Your blood counts, kidney and liver function meet lab limits – the study team will check this.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill (GFH375) against a standard chemotherapy (docetaxel) for advanced lung cancer with a specific KRAS G12D mutation. If you have already tried platinum chemo and an immunotherapy, this trial might offer a new option.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests a combination of two drugs, GH21 and D-1553, for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination works better than each drug alone.
This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.
This trial tests a combination of two experimental drugs (SY-5933 and CT-707) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective.
This trial tests a new targeted drug, HS-10529, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth in patients who have already tried standard therapies.
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.